BARBARA ANN KARMANOS CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1995-01-01

Employees: 5K

Market Cap: -

Website: http://www.karmanos.org

Clinical Trials

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

Phase 2

Completed

Conditions: Recurrent Pleural Malignant Mesothelioma
Stage IV Pleural Mesothelioma

Interventions: Drug: Nintedanib

First Posted Date: 2015-10-05

Last Posted Date: 2021-12-09

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 20

Registration Number: NCT02568449

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States

EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma

Phase 1

Withdrawn

Conditions: Adult Gliosarcoma
Adult Brain Glioblastoma
Recurrent Brain Neoplasm

Interventions: Biological: EGFRBi-Armed Autologous T Cells
Other: Laboratory Biomarker Analysis

First Posted Date: 2015-08-13

Last Posted Date: 2016-02-15

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT02521090

Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer

Phase 1

Completed

Conditions: Adnexal Mass
Ovarian Neoplasm
Recurrent Ovarian Carcinoma
Borderline Ovarian Epithelial Tumor
Ovarian Clear Cell Tumor
Ovarian Serous Tumor
Ovarian Endometrioid Tumor

Interventions: Drug: Dexamethasone
Other: Laboratory Biomarker Analysis
Drug: Valproic Acid

First Posted Date: 2015-08-11

Last Posted Date: 2019-08-14

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 50

Registration Number: NCT02520115

Locations: 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Karmanos Cancer Institute at McLaren Bay Region, Bay City, Bay City, Michigan, United States

PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer

Phase 1

Completed

Conditions: Stage II Prostate Adenocarcinoma
Stage I Prostate Adenocarcinoma
Stage III Prostate Adenocarcinoma

Interventions: Drug: Antiandrogen Therapy
Other: Laboratory Biomarker Analysis
Drug: Multitargeted Tyrosine Kinase Inhibitor PLX3397
Radiation: Radiation Therapy

First Posted Date: 2015-06-15

Last Posted Date: 2020-10-06

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 8

Registration Number: NCT02472275

Locations: 🇺🇸
Karmanos Cancer Institute at McLaren Northern Michigan - Petoskey Radiation Oncology, Petoskey, Michigan, United States
🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Karmanos Cancer Institute at McLaren Northern Michigan- Petoskey Medical Oncology, Petoskey, Michigan, United States

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent

Phase 1

Withdrawn

Conditions: Malignant Ovarian Serous Tumor
Recurrent Ovarian Carcinoma
Stage IIIC Primary Peritoneal Cancer
Stage IV Ovarian Cancer
Stage IIIA Ovarian Cancer
Stage IIIB Primary Peritoneal Cancer
Stage IV Primary Peritoneal Cancer
Malignant Ovarian Clear Cell Tumor
Recurrent Fallopian Tube Carcinoma
Stage IIIA Fallopian Tube Cancer

Interventions: Biological: Aldesleukin
Biological: HER2Bi-Armed Activated T Cells
Other: Laboratory Biomarker Analysis
Biological: Sargramostim

First Posted Date: 2015-06-12

Last Posted Date: 2016-02-17

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT02470559

MK-3475 as Maintenance Therapy in Extensive Stage SCLC

Phase 2

Completed

Conditions: Extensive Stage Small Cell Lung Carcinoma

Interventions: Biological: Pembrolizumab
Other: Laboratory Biomarker Analysis

First Posted Date: 2015-02-09

Last Posted Date: 2022-10-14

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 45

Registration Number: NCT02359019

Locations: 🇺🇸
Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 2 locations

Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer

Not Applicable

Recruiting

Conditions: Recurrent Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Other: cytology specimen collection procedure
Other: laboratory biomarker analysis

First Posted Date: 2014-06-30

Last Posted Date: 2024-07-18

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 1020

Registration Number: NCT02178163

Locations: 🇺🇸
KCI at McLaren Central Michigan, Mount Pleasant, Michigan, United States
🇺🇸
KCI at Northern Michigan, Petoskey, Michigan, United States
🇺🇸
KCI at McLaren Flint, Flint, Michigan, United States

and more 8 locations

Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer

Not Applicable

Terminated

Conditions: Recurrent Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: docetaxel
Drug: pemetrexed disodium
Drug: gemcitabine hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2014-05-22

Last Posted Date: 2020-09-24

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 4

Registration Number: NCT02145078

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate
Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions: Drug: enzalutamide
Drug: bicalutamide
Procedure: orchiectomy
Drug: leuprolide acetate
Drug: goserelin acetate
Other: laboratory biomarker analysis

First Posted Date: 2014-02-10

Last Posted Date: 2023-05-10

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 71

Registration Number: NCT02058706

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States

and more 1 locations

Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

Not Applicable

Completed

Conditions: Contiguous Stage II Adult Burkitt Lymphoma
Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma
Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma
Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma
Adult Grade III Lymphomatoid Granulomatosis
B-cell Chronic Lymphocytic Leukemia
Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Contiguous Stage II Adult Lymphoblastic Lymphoma
Contiguous Stage II Grade 1 Follicular Lymphoma
Contiguous Stage II Grade 2 Follicular Lymphoma

Interventions: Drug: bortezomib
Biological: filgrastim
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2014-01-15

Last Posted Date: 2021-05-10

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 23

Registration Number: NCT02037256

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Home Terms & Conditions Privacy Policy